Peptech name change to Arana Therapeutics
Peptech has announced an official name change to Arana Therapeutics. The company’s ASX code will change to AAH this week and its code on the London Stock Exchange has been changed to AAHx.
Arana Therapeutics, created by the merger of Peptech and EvoGenix in August 2007, is focused on developing antibody/protein-based new generation products and platforms for the treatment of inflammatory diseases and cancer.
“This final step in the merger of Peptech and EvoGenix creates a true global player in the antibody therapeutics sector,” said Robin Beaumont, chairman of Arana Therapeutics.
“As well as critical mass, Arana Therapeutics has the right mix of people, skills, technologies and, most importantly, financial backing to achieve international recognition. Our key focus now is to rapidly develop our exciting product pipeline.”
Vaxxas appoints former Merck Global Vaccines President David Peacock as CEO
To lead the commercialisation of Vaxxas's proprietary high‑density microarray patch (HD‑MAP)...
Optics11 Life appoints Jacquelien ten Dam as CEO
Optics11 Life plans to accelerate its commercial growth in key markets while building strategic...
Epilepsy pioneer elected President of Aust Academy of Science
Laureate Professor Sam Berkovic — one of the world's most respected neurologists...
